For millions of people, their best night’s sleep must start with a diagnosis.” “We believe Ectosense’s digital and easy-to-use solutions in the hands of both sleep lab technicians and consumers worldwide can help significantly increase diagnoses, as well as general awareness of this highly prevalent, 100% treatable disease. “Sleep labs and home tests each have critical roles to play in expanding our reach and identifying the 936 million people worldwide who have sleep apnea,” says Jim Hollingshead, ResMed president of Sleep & Respiratory Care, in a release. ResMed will continue to sell its ResMed ApneaLink Air home sleep test device “it’s enabled sleep labs, doctors, and other clinicians to process over 1.5 million diagnostic sleep tests in the cloud,” according to the ResMed spokesperson. A ResMed spokesperson notes in an email to Sleep Review that the NightOwl disposable HST is consumer-friendly because “it is digital and easy to use in lab or at home.” ResMed has distributed NightOwl in Australia and India since 2020 under the brand “ResMed onesleeptest,” and has been a minority investor in Ectosense since July 2020. ResMed today has completed the acquisition of Ectosense, makers of the NightOwl cloud-connected home sleep test (HST).Įctosense’s FDA-approved NightOwl is sold in the United States, Australia, New Zealand, India, and parts of Europe.
0 kommentar(er)
